209 related articles for article (PubMed ID: 31535597)
1. Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence.
Schuster RM; Potter K; Vandrey R; Hareli M; Gilman J; Schoenfeld D; Evins AE
J Psychopharmacol; 2020 Feb; 34(2):197-210. PubMed ID: 31535597
[TBL] [Abstract][Full Text] [Related]
2. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users.
Schwilke EW; Gullberg RG; Darwin WD; Chiang CN; Cadet JL; Gorelick DA; Pope HG; Huestis MA
Addiction; 2011 Mar; 106(3):499-506. PubMed ID: 21134021
[TBL] [Abstract][Full Text] [Related]
3. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
[TBL] [Abstract][Full Text] [Related]
4. Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.
Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
J Anal Toxicol; 2020 Jan; 44(1):1-14. PubMed ID: 31095692
[TBL] [Abstract][Full Text] [Related]
5. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.
Lowe RH; Abraham TT; Darwin WD; Herning R; Cadet JL; Huestis MA
Drug Alcohol Depend; 2009 Nov; 105(1-2):24-32. PubMed ID: 19631478
[TBL] [Abstract][Full Text] [Related]
6. Elimination of 11-nor-9-carboxy-delta-9-tetrahydrocannabinol when normalized to urinary creatinine.
Beardsley GD; Christensen JM
Res Commun Mol Pathol Pharmacol; 2007-2008; 120-121(1-6):67-78. PubMed ID: 21469505
[TBL] [Abstract][Full Text] [Related]
7. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?
Desrosiers NA; Lee D; Concheiro-Guisan M; Scheidweiler KB; Gorelick DA; Huestis MA
Clin Chem; 2014 Feb; 60(2):361-72. PubMed ID: 24185550
[TBL] [Abstract][Full Text] [Related]
8. Short communication: Urinary excretion of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol in a pregnant woman following heavy, chronic cannabis use.
Westin AA; Huestis MA; Aarstad K; Spigset O
J Anal Toxicol; 2009; 33(9):610-4. PubMed ID: 20040136
[TBL] [Abstract][Full Text] [Related]
9. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence.
Goodwin RS; Darwin WD; Chiang CN; Shih M; Li SH; Huestis MA
J Anal Toxicol; 2008 Oct; 32(8):562-9. PubMed ID: 19007504
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.
Schlienz NJ; Cone EJ; Herrmann ES; Lembeck NA; Mitchell JM; Bigelow GE; Flegel R; LoDico CP; Hayes ED; Vandrey R
J Anal Toxicol; 2018 May; 42(4):232-247. PubMed ID: 29300962
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users.
Smith-Kielland A; Skuterud B; Mørland J
J Anal Toxicol; 1999 Sep; 23(5):323-32. PubMed ID: 10488918
[TBL] [Abstract][Full Text] [Related]
12. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana.
Huestis MA; Mitchell JM; Cone EJ
J Anal Toxicol; 1996 Oct; 20(6):441-52. PubMed ID: 8889681
[TBL] [Abstract][Full Text] [Related]
14. Assessing cannabis consumption frequency: Is the combined use of free and glucuronidated THCCOOH blood levels of diagnostic utility?
Hädener M; Martin Fabritius M; König S; Giroud C; Weinmann W
Drug Test Anal; 2017 Jul; 9(7):1043-1051. PubMed ID: 27732768
[TBL] [Abstract][Full Text] [Related]
15. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.
Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Herning RI; Cadet JL; Huestis MA
J Anal Toxicol; 2009 Oct; 33(8):469-77. PubMed ID: 19874654
[TBL] [Abstract][Full Text] [Related]
16. One Month of Cannabis Abstinence in Adolescents and Young Adults Is Associated With Improved Memory.
Schuster RM; Gilman J; Schoenfeld D; Evenden J; Hareli M; Ulysse C; Nip E; Hanly A; Zhang H; Evins AE
J Clin Psychiatry; 2018 Oct; 79(6):. PubMed ID: 30408351
[TBL] [Abstract][Full Text] [Related]
17. Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections.
Smith ML; Barnes AJ; Huestis MA
J Anal Toxicol; 2009 May; 33(4):185-9. PubMed ID: 19470219
[TBL] [Abstract][Full Text] [Related]
18. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.
Gustafson RA; Kim I; Stout PR; Klette KL; George MP; Moolchan ET; Levine B; Huestis MA
J Anal Toxicol; 2004 Apr; 28(3):160-7. PubMed ID: 15107145
[TBL] [Abstract][Full Text] [Related]
19. Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users.
Lewis J; Molnar A; Allsop D; Copeland J; Fu S
Int J Legal Med; 2016 Jan; 130(1):147-52. PubMed ID: 26233612
[TBL] [Abstract][Full Text] [Related]
20. Urinary clearance of 11-nor-9-carboxy-Δ
Sempio C; Huestis MA; Kaplan B; Klawitter J; Christians U; Henthorn TK
Drug Test Anal; 2022 Aug; 14(8):1368-1376. PubMed ID: 35332698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
